← Back
$APLS All transactions

Apellis Pharmaceuticals, Inc.

M 10b5-1 Plan

$ Value

$0

Shares

15,000

Price

$0

Filed

Sep 10

Insider

Name

Sullivan Timothy Eugene

Title

Chief Financial Officer

CIK

0001707000

Roles

Officer

Transaction Details

Transaction Date

2025-09-08

Code

M

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

242,903

Footnotes

This is a scheduled exercise & sale from 10b5-1 trading plan dated June 9, 2025. | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.67 to $27.98, inclusive. The reporting person hereby undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. | The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein. | This option was granted on October 18, 2017 and fully vested.

Filing Info

Accession No.

0001127602-25-021248

Form Type

4

Issuer CIK

0001492422

Sullivan Timothy Eugene's History

Date Ticker Type Value
2026-04-17 APLS G $0
2026-04-17 APLS G $0
2026-01-28 APLS A $0
2026-01-22 APLS $224K
2026-01-20 APLS $57K
2026-01-13 APLS $86K
2025-10-21 APLS M $100K
2025-10-21 APLS $280K
2025-10-21 APLS M $0
2025-09-08 APLS M $150K

Other Insiders at APLS (90d)

Insider Bought Sold Last
Dolsten Mikael 2026-02-27
Watson David O.
General Counsel
2026-01-28
Deschatelets Pascal
Chief Scientific Officer
2026-01-28
Francois Cedric
Chief Executive Officer
2026-03-11
Sullivan Timothy Eugene
Chief Financial Officer
2026-04-17
O'Brien Stephanie Monaghan 2026-04-06
Nicholson Nur
Chief Technical Officer
2026-01-28
Chopas James George
VP/Chief Accounting Officer
2026-01-28
DeLong Mark Jeffrey
Chief Business & Strat Officer
$8K 2026-02-11
Boucher Kelley
Chief People Officer
2026-01-28
MELTZER LESLIE
Chief Research and Development
2026-01-28